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Abstract 
Background: The requirement of promyelocytic leukaemia protein (PML) in interferon (IFN)-induced cell apoptosis 
is well-established. However, the exact mechanisms by which the multiple isoforms of PML protein participate in this 
process remain not well-understood. We previously demonstrated that PML isoform II (PML-II) positively regulates 
induced gene expression during a type I IFN response and evaluate here how PML-II contributes to IFNα-induced cell 
death.
Methods: HeLa cells were transiently depleted of PML-II by siRNA treatment and the response of these cells to treat-
ment with IFNα assessed by molecular assays of mRNA and proteins associated with IFN and apoptosis responses.
Results: In HeLa cells, death during IFNα stimulation was reduced by prior PML-II depletion. PML-II removal also 
considerably decreased the induced expression of pro-apoptotic ISGs such as ISG54 (IFIT2), and substantially impaired 
or prevented expression of PUMA and TRAIL, proteins that are associated with the intrinsic and extrinsic apoptotic 
pathways respectively. Thirdly, PML-II depletion enhanced ERK and AKT pro-survival signaling activation suggesting 
that PML-II normally suppresses signaling via these pathways, and that lack of PML-II hence led to greater than normal 
activation of AKT signaling upon IFNα stimulation and consequently increased resistance to IFNα-induced apoptosis.
Conclusions: The positive contribution of PML-II to the expression of various IFNα-induced pro-apoptotic proteins 
and its inhibition of pro-survival signaling together provide a mechanistic explanation for reduced apoptosis under 
conditions of PML deficiency and may account for at least part of the role of PML as a tumor suppressor gene.
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Background
Type I interferons (IFNα, β) are produced and secreted 
by cells in response to pathogen or damage sensing. They 
signal via cell surface receptors to activate expression of 
a large class of IFN-stimulated genes (ISGs), products 
from which act in multiple pathways to limit pathogen 
growth (reviewed in [1]). Whilst IFNα is thought to have, 
broadly, a cell survival effect on normal cells, protecting 
them from virus-induced apoptosis, it can induce apop-
tosis in tumour cells [2]. Indeed, IFNα has been used for 
the treatment of several types of haematological malig-
nancies and solid tumors [3, 4].
Apoptosis can be triggered by either external or inter-
nally generated signals [5]. Several ISGs have been iden-
tified that have pro-apoptotic functions, for example 
ISG15 [6], ISG54 (IFIT2) [7, 8], XAF-1 (XIAP associated 
factor-1) & CD95 (Fas/APO-1) [9], and PML itself [10]. 
TRAIL/Apo2L (tumour necrosis factor-related apop-
tosis-inducing ligand) has also been demonstrated to 
be important for IFNα-mediated growth inhibition and 
apoptosis in cancer cells such as melanoma, myeloma and 
hepatocellular carcinoma [11–13]. Moreover, the expres-
sion of PUMA, an important pro-apoptotic protein of the 
intrinsic pathway, was also increased by IFNα stimula-
tion in human myeloma cells [14]. As well as the action 
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of specific ISGs, the inhibition of pro-survival signaling 
via the extracellular signal-regulated kinase (ERK) and 
phosphatidyl-inositol 3-kinase (PI3K)/AKT pathways is 
also an important mechanism for IFNα-mediated anti-
tumour function. IFNα transiently diminished the phos-
phorylation of ERK in hepatocellular carcinoma cell lines 
suggesting an inhibition of this pathway [15]. IFNβ inhi-
bition of AKT signaling was found to potentiate cispl-
atin-induced apoptosis in Hela cells [16] although PI3K 
signaling via mTOR was, in contrast, necessary for apop-
tosis induction in a multiple myeloma cell line [17].
Promyelocytic leukemia (PML) protein, an ISG prod-
uct [18, 19], has multiple isoforms due to mRNA alter-
native splicing and post-translational modification, the 
regulation of which is not fully understood [20, 21]. The 
major isoforms are functionally distinct by virtue of their 
C-terminal domains, which recruit different interacting 
partners [22, 23]. The largest isoforms (PML-I and PML-
II) are thought to be the most abundant, with other iso-
forms being very minor components in normal cells and 
more abundant in tumour cells, but still less than PML-I/
II [24]. The tumour suppressive function of PML was first 
suggested by discovery of its disruption in a chromosome 
rearrangement that is characteristic of acute PML [25, 
26]; the resulting fusion protein acts as a dominant-nega-
tive to block the activity of normal PML protein [10]. The 
tumour suppressive activity of PML was later extended 
to various solid tumours [27]. PML protein levels when 
compared to normal cells were found to be low in cancers 
including cervical, breast, lung and colon among others, 
correlating PML deficiency with tumorigenesis [28, 29], 
while loss of the Pml gene in a mouse model markedly 
accelerated tumour onset, incidence and progression 
[30]. It has been suggested that PML prevents cancer by 
inactivating nuclear AKT activity [30].
Several studies have shown that PML is required 
for efficient induction of apoptosis. Cells from PML-
deficient mice showed severe apoptotic defects includ-
ing a strongly decreased sensitivity to IFN-induced and 
death receptor-mediated apoptosis [10], while growth 
inhibition by IFNα in myeloma cells correlated with the 
presence of PML [11]; IFNα-induced apoptosis in hepa-
tocellular carcinoma also involved PML [12]. In addition, 
cytoplasmic PML was required for apoptosis signaled by 
endoplasmic reticulum (ER) stress, opposing AKT sur-
vival signaling [31]. Lastly, the expression level of PML 
protein was shown to be closely related to the induction 
of cell death [32]. All these studies suggest that PML pro-
tein is an essential participant in or regulator of apoptosis 
induced by multiple routes including by IFN. However, 
the exact mechanism of this involvement remains to be 
completely understood. Among all the PML isoforms, 
PML isoform II (PML-II) is considered to be one of the 
most abundant isoforms suggesting a main contribution 
to PML functions [24, 33]. PML-II in particular poten-
tiates the type I IFN response and ISG expression [34], 
suggesting that it may be an important player in IFN-
mediated apoptosis. Here we show that loss of PML-II 
prior to IFNα stimulation results in reduced pro-apop-
totic gene induction and increased cell survival signaling, 




Human cervical cancer cell line, HeLa, was cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) 
supplemented with 10% (v/v) foetal bovine serum (FBS) 
(Sigma) at 37 C in a 5%  CO2 incubator. IFNα was from 
PBL Assay Science, poly(I:C) was bought from Sigma. 
PML, PML-I, PML-II, PML-V and control siRNA 
sequences (Additional File 1: Table S1) were synthesized 
by Ambion; Lipofectamine 2000 was purchased from 
Invitrogen.
Flow cytometry
Cell death/apoptosis was determined by flow cytometry. 
Following 100  pmol/L siRNA transfection and IFNα or 
1 μg/ml poly(I:C) stimulation at appropriate time points 
described, HeLa cells in 48-well cultures were released 
with trypsin and stained with 1  µg/m1of propidium 
iodide (PI) and incubated on ice for 20–30  min in the 
dark. After twice washing with cold PBS, cell staining was 
quantified using a FACSCanto II flow cytometer (BD Bio-
sciences). Assays were performed in duplicate.
SYBR‑Green quantitative PCR
RNA was harvested from HeLa cell 24-well cultures 
using GenElute Mammalian Total RNA Miniprep Kit 
(Sigma-Aldrich) following the manufacturer’s instruc-
tions. Reverse transcriptions were performed using GoS-
cript™ reverse transcriptase (Promega). Quantitative 
PCR (qPCR) reactions used SYBR-Green qPCR Mas-
ter Mix and a Stratagene Mx3005P light cycler (Agilent 
Technologies). qPCR primers used in this study are listed 
in Supplementary Table  2. Data were analyzed using 
Agilent Technologies system software, with quantifica-
tion based on Ct difference performed according to the 
“delta–delta Ct method” [35]. Target gene expression was 
normalized against expression of the housekeeping genes 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 
β-actin. All samples were analysed in triplicate.
Western‑blotting
Cells were lysed directly with SDS sample buffer (4% 
sodium dodecyl sulfate [SDS], 20% glycerol, 50  mM 
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Tris HCl (pH 6.8)), proteins separated by SDS polyacryla-
mide gel electrophoresis and transferred to nitrocellu-
lose membrane. Membranes were incubated overnight 
with specific primary antibodies diluted in blocking 
buffer. These included: TRAIL, PUMA, AKT, phospho-
AKT(Ser473), phospho-p70S6K1(Thr389), ERKp44/p42, 
phospho-ERK(Thr202/Tyr204) and p-STAT1(Tyr701) 
from Cell Signaling Technology; MCL-1 and GAPDH 
from Santa Cruz Biotechnology; BCL-2 from DaKo; 
ISG15, ISG54, OAS1 and PML from Proteintech; β-actin 
from Millipore. After washing, bound antibodies were 
detected with fluorescent-conjugated secondary anti-rab-
bit or anti-mouse antibodies (Enzo Life Sciences), then 
visualized and quantified with an Odyssey system (Pierce, 
Waltham, MA, USA).
Results
PML‑II regulates type I interferon‑induced cell death
To investigate the biological role of PML-II in IFNα-
induced cell death, we employed PML-II specific siRNA 
in HeLa cells, which are a cervical cancer cell line that 
has been shown to express PML-II and to be susceptible 
to IFNα-induced apoptosis [36, 37]; PML-II is a major 
PML isoform in these cells (Fig.  1A). Reflecting this 
abundance, siPML-II greatly inhibited PML-II expres-
sion but also detectably reduced total PML while PML 
siRNA (targeting all isoforms) not only inhibited PML 
expression but also decreased the expression of PML-
II to a level similar to that achieved by PML-II siRNA 
(Fig.  1B). IFNα stimulation upregulated the expressions 
of all PML and PML-II specifically, and this upregula-
tion was completely inhibited by either PML or PML-II 
siRNA (Fig.  1B). Reduced mRNA led to reduced PML 
protein (Fig. 1C, D) and, of the major isoforms, PML-II 
siRNA only had a significant effect on its expected tar-
get (Fig.  1E). Cell death increased with increasing dose 
and duration of exposure to IFNα (Fig. 1F). Importantly, 
knockdown of PML-II prior to IFNα treatment elimi-
nated IFNα-induced cell death (Fig.  1G, H) whereas 
depletion of another isoform, PML-V, increased cell 
death independent of IFNα (Fig.  1H). We also tested 
the impact of PML-II depletion on cell death caused by 
poly(I:C), a synthetic analog of double-stranded RNA 
that is an effective type I IFN inducer [34, 38]. poly(I:C) 
stimulation quickly and effectively induced cell death in 
a dose-dependent pattern (Fig. 1I) and prior depletion of 
PML-II reduced this cell death response (Fig. 1J). These 
findings suggested that PML-II may have a general func-
tion regulating type I IFN-mediated apoptosis in HeLa 
cells that we investigated further.
PML‑II positively regulates IFNα‑induced pro‑apoptotic 
protein expression
As expected, expression of ISGs, including ISG15, ISG54 
and OAS1, was greatly increased by IFNα (Fig.  2A–C). 
Expression of the death receptor TRAIL [13] and the 
pro-apoptotic gene PUMA was also rapidly induced by 
IFNα (Fig.  2D, E), although the scale of PUMA induc-
tion was much lower than for the ISGs and TRAIL. In 
contrast, IFNα stimulation had no effect on the expres-
sion of the anti-apoptotic BCL family members, MCL-1 
(Fig.  2F) and BCL-2 (Fig.  2G). The impact of IFNα on 
TRAIL, ISG15, ISG54, OAS1, BCL-2 and MCL-1 was 
further confirmed at the protein level (Fig. 2H, I, quan-
tified in Fig.  2J, K). We showed previously that IFNα-
induced ISG mRNA levels were reduced substantially by 
prior depletion of PML-II [34]. As many of these prod-
ucts are pro-apoptotic [6, 8, 9], we next investigated the 
effect of PML-II depletion on apoptosis signaling com-
ponents. Reduced expression of PML-II and ISG54 was 
achieved as expected (Fig. 3A, B). TRAIL induction was 
also greatly decreased at both the mRNA (Fig.  3C) and 
protein level (Fig.  3D) by PML-II depletion while the 
smaller scale induction of PUMA mRNA was abolished 
Fig. 1 IFNα-induced cell death is PML-II dependent. A HeLa cells were stimulated with 1000 U/ml IFNα or not and PML isoform mRNA levels 
measured by SYBR-Green qPCR. The relative expression level of each PML isoform was quantified relative to β-actin. B 30–50% confluent HeLa cells 
were transfected with siPML-II, siPML or control siRNA for 48 h, and following 1000 U/ml IFNα or mock stimulation for 12 h, cells were collected 
and mRNA levels for PML-II and total PML were measured by SYBR-Green qPCR. The relative mRNA expression of each gene was quantified relative 
to GAPDH, and normalized to the level of unstimulated control siRNA-transfected cells. C HeLa cells, D HEK293 cells were transfected with PML-II 
or control siRNA for 48 h, then stimulated with 1000 U/ml IFNα at the described time points or 1 μg/ml poly(I:C) for 12 h. Total protein lysates 
were analyzed by western blotting for PML and PML-II, respectively. E Hela cells were transfected with either siPML-II or control siRNA for 48 h, and 
stimulated with 1000 U/ml IFNα for 12 h, then mRNA levels of PML-I, PML-II, PML-IV and PML-V were measured by SYBR-Green qPCR as in (B). F HeLa 
cells were treated with 1000 U/ml IFNα for 24 h or 48 h, and cell death quantified by PI staining and flow cytometry. G Hela cells were transfected 
with either siPML-II or control siRNA for 24 h, and following stimulation for 24 h with amounts of IFNα as indicated, cell death was quantified as in 
(F). H HeLa cells were transfected with either siPML-II or control siRNA for 12 h, then following 1000 U/ml IFNα stimulation for 48 h, cell death was 
detected as (F). I HeLa cells were transfected with the amounts of poly(I:C) indicated for 24 h, then cell death quantified as in (F). J HeLa cells were 
transfected with siRNA as in (F) for 24 h, then with 1 μg/ml poly(I:C) for 24 h and cell death quantified as in (F). Error bars show standard deviation 
among technical replicates
(See figure on next page.)
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(Fig.  3E). The effect of PML-II on PUMA protein level 
was more complex (Fig. 3F). In uninduced cells, amounts 
of PUMA were two-fold greater in the absence of PML-
II, suggesting increased stability since basal mRNA lev-
els were if anything marginally reduced. Following IFNα 
stimulation, PUMA protein accumulated with similar 
kinetics to its mRNA in the presence of PML-II but in its 
absence not only was there no PUMA protein induction, 
in line with the lack of mRNA induction, but protein lev-
els actually declined. In contrast, PML-II depletion had 
little effect on the expression of anti-apoptotic BCL fam-
ily members BCL-2 and Bcl-xL (Fig. 3G, H).
PML‑II regulates ERK and AKT signaling
ERK and AKT signaling pathways link with prolifera-
tion and/or survival of various cancer cell lineages [39, 
Fig. 1 (See legend on previous page.)
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40]. We thus tested the effect of PML-II depletion on 
these pro-survival signals. Without any IFN stimula-
tion, the phosphorylation level of ERK kinase (p-ERK) 
was increased by depleting PML-II (Fig.  4A), and the 
expression of ERK-dependent genes c-Fos and c-Myc 
was also upregulated (Fig.  4B), both indicating that 
PML-II has an inhibitory effect on ERK signaling. ERK 
protein levels were unchanged (Fig.  4C). Similarly, 
the levels of phospho-AKT (p-AKT) and phosphoryl-
ated p70S6K1, a downstream effector of AKT, were 
also enhanced by the depletion of PML-II (Fig.  4A), 
indicating that PML-II also inhibits this anti-apoptotic 
pathway.
Subsequently, we investigated the effect of PML-II on 
ERK signaling under the condition of IFNα stimulation. 
Upon IFNα addition to control cells, the level of phos-
pho-ERK (p-ERK) began to increase within 5 min, peaked 
at 30 min and returned near to the basal level within one 
hour, and this low level of p-ERK was maintained in the 
following hours (Fig.  4C, D). Importantly, even under 
conditions of PML-II depletion, IFNα treatment still 
increased p-ERK levels further from the elevated basal 
Fig. 2 IFNα induces pro-apoptotic gene expression. HeLa cells were stimulated with 1000 U/ml IFNα and collected at different time points. (A–F) 
The mRNA levels of A ISG15, B ISG54, C OAS1, D TRAIL, E PUMA, F MCL-1 and G BCL-2 were measured by SYBR Green qPCR. The mRNA level of 
each gene was quantified relative to GADPH and normalized to the time zero value. Results are presented as mean ± SD of technical triplicate 
experiments. H–I Whole cell protein was analyzed by western blotting for ISG15, ISG54, OAS1, PML, p-STAT1, TRAIL, BCL-2 and MCL-1. β-actin was 
used as loading control. (J–K) The protein bands in panel H and I were visualized and quantified with an Odyssey system (Pierce), normalized to 
β-actin
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level (Fig.  4C), suggesting an intrinsic inhibitory func-
tion of PML-II on ERK signaling, which was then further 
increased by IFNα stimulation independent of PML-II.
The short-term effect of IFNα on AKT signaling was 
similar to that on ERK. The level of p-AKT was elevated 
at 15 min post-stimulation, and then declined to the basal 
level at 60 min, and a similar result was also observed for 
phos-p70S6K1 (Fig.  5A). However, an inhibitory effect 
on p-AKT was observed after long-term IFNα stimula-
tion (Fig.  5B, C). This long-term inhibition of the AKT 
pathway by IFNα could make an important contribution 
to IFNα-induced apoptosis. Finally, the role of PML-II in 
IFNα-regulated AKT signaling was determined (Fig. 5A, 
D). As observed for ERK, removing PML-II increased the 
base level of p-AKT. Some IFNα-induced drop in p-AKT 
occurred from this higher base level early post-stimula-
tion, but the level rebounded by 8 h to amounts consider-
ably higher than pre-stimulation (Fig. 5D, E). Altogether, 
these data demonstrated a similar pattern of effect of 
IFNα on AKT and ERK signaling in HeLa cells, with a 
transient increase and subsequent decrease in AKT and 
ERK signaling. PML-II repressed basal ERK and AKT 
signaling, limited the duration of stimulated ERK sign-
aling during an IFN response, and inhibited longer term 
activation of the AKT pathway by IFNα signaling.
Discussion
Previous work has established that PML is required for 
cell death. The data presented here show that the PML-
II isoform specifically plays an important role in regulat-
ing cell death. Cell death following IFNα-stimulation was 
correlated with induction of pro-apoptotic factors such 
as TRAIL and PUMA, and with reduction in pro-survival 
signalling via AKT and ERK. When PML-II was depleted 
prior to IFNα treatment, both cell death and pro-apop-
totic gene induction were reduced and the inhibition of 
Fig. 3 PML-II depletion downregulates pro-apoptotic gene expression. Hela cells were transfected with either PML-II siRNA or control siRNA for 
48 h. Cells were stimulated with 1000 U/ml IFNα and were collected at described time points. (A–C, E, G, H) The mRNA expression levels of A PML-II, 
B ISG54, C TRAIL, E PUMA, G Bcl2 and H Bcl-xL were measured by SYBR Green qPCR. (D, F) The expression levels of D TRAIL and F PUMA proteins 
were detected by western blotting (left panels) and quantified by Odyssey system relative to β-actin (right panels). Error bars show standard 
deviation among technical replicates
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pro-survival signalling normally produced by IFNα treat-
ment was reversed. Because PML-II, being the product 
of an ISG, was itself strongly induced by IFNα treatment, 
its inhibition of pro-survival signalling will be further 
enhanced during an IFN response.
In this study, PML-II specific siRNA treatment not only 
greatly reduced PML-II but also significantly reduced 
total PML mRNA expression. This probably is because 
PML-II is one of the most expressed PML isoforms [24, 
33]. The depletion of PML-II diminished cell death dur-
ing IFN or poly(I:C) stimulation. This is consistent with 
the previous observations that PML protein is required 
for IFN-induced apoptosis [10, 32], and suggests that 
PML-II is one of the important isoforms involved in the 
process. HeLa cell death was observed following IFNα 
treatment in a dose- and a time-dependent pattern. The 
amount of dead cells was limited, probably because both 
the induction of pro-apoptotic proteins by IFNα and the 
reduction in pro-survival signalling were not sustained. 
Changes in expression level/activation level of these pro-
teins peaked at 4–6  h after stimulation. HeLa cells also 
have multiple abnormalities and are relatively resistant to 
apoptosis because levels of p53 are kept low by the pres-
ence of human papillomavirus 18 E6 protein [41]. Moreo-
ver, cancer cells may respond differently to the different 
IFN subtypes. IFNβ is more potent compared to IFNα 
in inducing apoptosis in various cancer cells including 
melanoma, ovarian carcinoma and multiple myeloma cell 
lines [42–44]. This may explain why poly(I:C), an effec-
tive IFNα/β inducer, caused greater death in HeLa cells 
than IFNα alone.
During an IFN response, PML-II positively regulates 
the expression of pro-apoptotic ISGs [6, 8, 9]. Expres-
sion of TRAIL, which is the ligand for a death recep-
tor and an ISG important for IFN-induced apoptosis in 
melanoma [11], was also found here to be strictly regu-
lated by PML-II at both mRNA level and protein level, 
suggesting a role for PML-II in TRAIL death receptor-
mediated apoptosis. This finding is consistent with the 
previous observation that loss of total PML decreased 
TRAIL expression in hepatocellular carcinoma cells [42] 
and correspondingly impaired IFNα-induced apoptosis 
[12]. In the present study, IFNα stimulation also induced 
expression of PUMA, an important effector in the mito-
chondria-mediated cell apoptosis pathway, and this 
induction was reduced by depleting PML-II. Overexpres-
sion of PUMA was found previously to cause rapid and 
profound apoptosis in colorectal cancer cells [45] and its 
level was increased by IFNα treatment in multiple mye-
loma [14]. In contrast to these IFNα and PML-II depend-
ent increases in pro-apoptotic signaling components, the 
expression level of anti-apoptotic proteins of the BCL 
family was unaffected by IFNα stimulation. The involve-
ment of PML-II in expression of both PUMA and TRAIL 
during IFNα-stimulation suggests that it is a positive 
regulator in both mitochondrial-mediated (PUMA) and 
death receptor-mediated (TRAIL) apoptotic pathways.
As well as inducing pro-apoptotic functions, type 1 IFN 
may exert anti-proliferative and pro-apoptosis activity by 
down-regulating survival signaling. The effects of IFNs 
on ERK and AKT signaling have been reported previ-
ously but with differing conclusions as to their activation 
[46–49] or suppression [15, 16, 50]. In the present study, 
we observed a transient activation of ERK and AKT sig-
nalling by IFNα in HeLa cells, however, when cells are 
exposed constitutively to IFNα, this situation is converted 
Fig. 4 PML-II regulates ERK signaling. (A, B) HeLa cells were 
transfected with siPML-II or control siRNA, and after 48 h cells were 
collected. A Total protein lysates were analyzed by western blotting 
for p-ERK, p-AKT and p-p70S6K1. B Total cell RNA was analyzed by 
SYBR Green qPCR for c-Fos and c-Myc mRNA expression; amounts are 
expressed relative to GAPDH and normalized to the siControl sample. 
Error bars show standard deviation among technical replicates. C, 
D HeLa cells were transfected with siPML or control siRNA for 48 h, 
then stimulated with 1000 U/ml IFNα and collected at the described 
time points. Total protein lysates were analyzed by western blotting 
for ERK, p-ERK and p-AKT as indicated. Panel C is taken from the same 
experiment as Fig. 1C; the control β-actin data are duplicated for ease 
of reference
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to a suppression of cancer cell survival, reflected in the 
long term inhibitory effect of IFNα on AKT signaling we 
observed.
PML-II was shown here to limit basal AKT activation 
and, during IFNα stimulation, PML-II depletion led to 
hyper-activation of AKT. PML (in total, not a specific 
isoform) is known to negatively regulate AKT activity 
by recruiting protein phosphatase 2A (PP2A) to PML-
NBs, thereby dephosphorylating and inactivating AKT 
and loss of all PML species impairs PP2A, so increasing 
AKT activity [30]. Our findings suggest that PML-II is an 
important isoform for PP2A regulation and could exert 
its observed effect on AKT via this route. PML-II was 
also found to negatively regulate ERK signaling. Basal 
ERK signaling is strictly controlled by various negative 
regulators including PP2A, dual-specificity phosphatases 
(DUSP) and SPROUTY (SPRY) family proteins [51–53]. 
The negative effect of PML-II on the ERK pathway may, 
like the AKT pathway, also be determined by control of 
PP2A, or it may affect another of these known regulators. 
Further study is required to investigate these questions.
Reduced levels of PML protein have been observed in 
human cancers of multiple origins [27–29]. An increase 
in pro-survival signaling under low/absent PML-II condi-
tions may be an important selective advantage for tumor 
growth. Several pathways that lead to increased turnover 
of all PML isoforms in tumour cells have been revealed 
[27], including ubiquitination by E6AP, an E3 ligase that 
is targeted in HPV-positive cervical carcinomas [54], and 
a hypoxia-induced mechanism mediated by KLHL20 
[55]; proteasome inhibitor treatment promoted PML re-
expression and restoration of PML-NBs in several PML 
negative tumor cell lines [28]. Recently, overexpression of 
PML was reported to inhibit cell growth and to signifi-
cantly increase cell apoptosis in gastric cancer cells (56). 
In view of the role of PML-II in the regulation of IFN-
mediated cell death, reduced or absent PML-II protein in 
tumors is also predicted to restrict the efficacy of IFNα 
anti-tumor activity.
Conclusions
Collectively, both negative regulation of ERK and AKT 
signaling pathways by PML-II and the support PML-II 
provides for full induction of pro-apoptotic gene expres-
sion contribute to the growth suppressive effects of IFNα 
that depend on PML-II (Fig.  6). In light of the findings 
presented here, preventing PML-II degradation by tar-
geting post-translational proteasome-dependent mecha-
nisms of PML turnover, or increasing PML-II levels by 
other means, should sensitize cancer cells to IFN-induced 
cell death and provide a useful additional approach to 
therapy.
Fig. 5 PML-II depletion increases AKT signaling. A HeLa cells were transfected and stimulated as Fig. 4C, and after the indicated times with IFNα, 
cells were lysed and the expression of p-AKT and p-p70S6K1 was detected by western blotting. B HeLa cells were stimulated with 1000 U/ml or 
5000 U/ml IFNα for 72 h, then cells were lysed for WB testing appropriate proteins. C The graph shows the quantification of WB bands in (B) by 
using the Odyssey system (Pierce), normalized to β-actin and expressed relative to non-IFNα stimulation. D Cells were treated as Fig. 4C, and were 
collected at different time points for testing p-ATK by western blotting. E The bands of p-AKT in (D) were quantified by using the Odyssey system, 
values normalized to β-actin and expressed relative to control siRNA cells treated without IFNα stimulation
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